Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722232 | 0.88 | TLR7 (0.50) | TLR8TSHRTLR7NUDT1MEN1 | |
| SCHEMBL6099996 | 0.87 | TLR8 (0.49) | TLR8TSHRTLR7NUDT1MEN1 | |
| SCHEMBL6105237 | 0.86 | TLR8 (0.48) | TLR8TSHRTLR7NUDT1MEN1 | |
| SCHEMBL18179115 | 0.86 | TLR7 (0.49) | TLR8TSHRTLR7NUDT1MEN1 | |
| SCHEMBL4308938 | 0.84 | TLR8 (0.47) | TLR8TSHRTLR7NUDT1MEN1 | |
| SCHEMBL4792464 | 0.84 | TLR7 (0.48) | TLR8TSHRTLR7NUDT1MEN1 | |
| SCHEMBL4319537 | 0.83 | TLR8 (0.48) | TLR8TSHRTLR7NUDT1MEN1 | |
| SCHEMBL4313003 | 0.83 | TLR8 (0.46) | TLR8TSHRTLR7NUDT1MEN1 | |
| SCHEMBL6723768 | 0.83 | TLR8 (0.48) | TLR8TSHRTLR7NUDT1MEN1 | |
| SCHEMBL8326936 | 0.83 | TLR8 (0.53) | TLR8TSHRTLR7NUDT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790961-B2 | REACTING A 3-AMINO-4-(SUBSTITUTED)AMINO-2-CHLOROQUINOLINE WITH AN ALKYLCARBONYL CHLORIDE TO FORM THE 2-ALKYLCARBOXAMIDE INTERMEDIATE | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20040122231-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-6686472-B2 | Process for preparing 1-substituted, 2-substituted 1-H-imidazo(4,5-c)quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20030212270-A1 | Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-6608201-B2 | Amidation of a 2-halo-3,4-diaminoquinoline with an acid chloride; dehalogenation, amination with ammonia; cyclization | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-19 | — | — | US | disclosed |
| US-20030119861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-06-26 | — | — | US | disclosed |
| US-6465654-B2 | ANTIVIRAL AGENTS, THAT INDUCE BIOSYNTHESIS OF INTERFERON, AND INHIBIT TUMOR FORMATION | 3M INNOVATIVE PROPERTIES COMPANY | 2002-10-15 | — | — | US | disclosed |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-22 | — | — | US | disclosed |
| US-6348462-B1 | VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-02-19 | — | — | US | disclosed |
| US-5977366-A | 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5741909-A | PHARMACEUTICAL COMPOSITIONS WHICH ACT AS ANTIVIRAL AGENTS, INDUCE BIOSYNTHESIS OF INTERFERON AND INHIBIT TUMOR FORMATION IN ANIMALS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5605899-A | VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5389640-A | Viricides, antitumor agents | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212270-A1 | Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines | IFNAR1, IRF3, IFNG | TLR8 382/4885TSHR 3625/4885MAPK1 2365/4885 |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | IFNAR1, IFNG, IRF3 | TLR8 335/4885TSHR 3765/4885MAPK1 2103/4885 |
| US-20040122231-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | UGT1A4, QARS1, HTR4 | TLR8 1825/4885TSHR 3510/4885MAPK1 2050/4885 |
| US-20030119861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | IRF3, IFNAR1, IFNG | TLR8 336/4885TSHR 3869/4885MAPK1 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.